The effect of YOCAS©® yoga for musculoskeletal symptoms among breast cancer survivors on hormonal therapy

Breast Cancer Research and Treatment

Volumn 150, Issue 3, 2015, Pages 597-604

  Peppone, Luke J ^a   Janelsins, Michelle C ^a   Kamen, Charles ^a   Mohile, Supriya G ^a   Sprod, Lisa K ^b   Gewandter, Jennifer S ^c   Kirshner, Jeffrey J ^d   Gaur, Rakesh ^e   Ruzich, Janet ^f   Esparaz, Benjamin T ^g   Mustian, Karen M ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA WILMINGTON   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

^d Hematology/Oncology Associates of Central New York   (United States)

^e Kansas City Clinical Oncology Research Program   (United States)

^f Pacific Cancer Research Consortium NCORP   (United States)

^g Heartland Cancer Research CCOP   (United States)

Author keywords

Aromatase inhibitor induced musculoskeletal symptoms; Arthralgias; Exercise; Yoga

Indexed keywords

AROMATASE INHIBITOR; TAMOXIFEN;

BREAST NEOPLASMS; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); COMPLICATION; FEMALE; HUMAN; KARNOFSKY PERFORMANCE STATUS; MIDDLE AGED; MUSCULOSKELETAL DISEASES; SURVIVOR; YOGA;

AROMATASE INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; KARNOFSKY PERFORMANCE STATUS; MIDDLE AGED; MUSCULOSKELETAL DISEASES; SURVIVORS; TAMOXIFEN; YOGA;

EID: 84939986390     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3351-1     Document Type: Article

References (26)

1. Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Lang I, Wardley A et al (2011) Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol 12:1101–1108. doi:10.1016/S1470-2045(11)70270-4
2. Arimidex TAoiCTG, Forbes JF, Cuzick J, Buzdar A, Howell A, JS Tobias, Baum M (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100 month analysis of the ATAC trial. Lancet Oncol 9:45–53. doi:10.1016/S1470-2045(07)70385-6
3. International Breast Cancer Study G, Group BIGC, Regan MM, Price KN, Giobbie-Hurder A, Thurlimann B, Gelber RD (2011) Interpreting breast international group (big) 1-98: a randomized, double-blind, phase iii trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer. Breast Cancer Res 13:209. doi:10.1186/bcr2837
4. Mouridsen HT (2006) Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women. Curr Med Res Opin 22:1609–1621. doi:10.1185/030079906X115667
5. Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T (2003) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98:1802–1810
6. Buzdar A, Howell A, Cuzick J, Wale C, Distler W, Hoctin-Boes G, Houghton J, Locker GY, Nabholtz JM (2006) Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 7:633–643. doi:10.1016/S1470-2045(06)70767-7
7. Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M et al (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25:486–492. doi:10.1200/JCO.2006.08.8617
8. Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thurlimann B, Paridaens R, Smith I, Mauriac L, Forbes JF, Price KN, Regan MM et al (2009) Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 361:766–776. doi:10.1056/NEJMoa0810818
9. Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, Sierra A, Hershman DL (2007) Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 25:3877–3883. doi:10.1200/JCO.2007.10.7573
10. Mao JJ, Stricker C, Bruner D, Xie S, Bowman MA, Farrar JT, Greene BT, DeMichele A (2009) Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer 115:3631–3639. doi:10.1002/cncr.24419
11. Henry NL, Giles JT, Ang D, Mohan M, Dadabhoy D, Robarge J, Hayden J, Lemler S, Shahverdi K, Powers P et al (2008) Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat 111:365–372. doi:10.1007/s10549-007-9774-6
12. Oberguggenberger A, Hubalek M, Sztankay M, Meraner V, Beer B, Oberacher H, Giesinger J, Kemmler G, Egle D, Gamper EM et al (2011) Is the toxicity of adjuvant aromatase inhibitor therapy underestimated? Complementary information from patient-reported outcomes (PROs). Breast Cancer Res Treat 128:553–561. doi:10.1007/s10549-011-1378-5
13. Group AT, Sestak I, Cuzick J, Sapunar F, Eastell R, Forbes JF, Bianco AR, Buzdar AU (2008) Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol 9:866–872. doi:10.1016/S1470-2045(08)70182-7
14. Blencowe NS, Reichl C, Gahir J, Paterson I (2010) The use of Nolvadex in the treatment of generic tamoxifen-associated small joint arthralgia. Breast 19:243–245. doi:10.1016/j.breast.2010.02.004
15. Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A (2008) Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 26:556–562. doi:10.1200/JCO.2007.11.5451
16. Dent S, DiValentin T, Vandermeer L, Spaans J, Verma S (2006) Long term toxicities in women with early stage breast cancer treated with aromatase inhibitors: data from a tertiary care center. Breast Cancer Res Treat 100(suppl 1):S190
17. Fontaine C, Meulemans A, Huizing M, Collen C, Kaufman L, De Mey J, Bourgain C, Verfaillie G, Lamote J, Sacre R et al (2008) Tolerance of adjuvant letrozole outside of clinical trials. Breast 17:376–381. doi:10.1016/j.breast.2008.02.006
18. Presant CA, Bosserman L, Young T, Vakil M, Horns R, Upadhyaya G, Ebrahimi B, Yeon C, Howard F (2007) Aromatase inhibitor-associated arthralgia and/or bone pain: frequency and characterization in non-clinical trial patients. Clin Breast Cancer 7:775–778. doi:10.3816/CBC.2007.n.038
19. Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, Kwan M, Gomez SL, Neugut AI (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126:529–537. doi:10.1007/s10549-010-1132-4
20. Ziller V, Kalder M, Albert US, Holzhauer W, Ziller M, Wagner U, Hadji P (2009) Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann oncol 20:431–436. doi:10.1093/annonc/mdn646
21. McCowan C, Shearer J, Donnan PT, Dewar JA, Crilly M, Thompson AM, Fahey TP (2008) Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 99:1763–1768. doi:10.1038/sj.bjc.6604758
22. Ulger O, Yagli NV (2010) Effects of yoga on the quality of life in cancer patients. Complement Ther Clin Pract 16:60–63. doi:10.1016/j.ctcp.2009.10.007
23. Galantino ML, Greene L, Archetto B, Baumgartner M, Hassall P, Murphy JK, Umstetter J, Desai K (2012) A qualitative exploration of the impact of yoga on breast cancer survivors with aromatase inhibitor-associated arthralgias. Explore: J Sci Heal 8:40–47. doi:10.1016/j.explore.2011.10.002
24. Carson JW, Carson KM, Porter LS, Keefe FJ, Seewaldt VL (2009) Yoga of awareness program for menopausal symptoms in breast cancer survivors: results from a randomized trial. Support Care Cancer: Offic J Multinatl Assoc Suppor Care Cancer 17:1301–1309. doi:10.1007/s00520-009-0587-5
25. Mustian KM, Sprod LK, Janelsins M, Peppone LJ, Palesh OG, Chandwani K, Reddy PS, Melnik MK, Heckler C, Morrow GR (2013) Multicenter, randomized controlled trial of yoga for sleep quality among cancer survivors. J Clin Oncol. doi:10.1200/JCO.2012.43.7707
26. American College of Sports M (2010) ACSM’s Guidelines for exercise testing and prescription. Lippincott Williams & Wilkins, Baltimore